109 related articles for article (PubMed ID: 17066095)
1. Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor-related apoptosis-inducing ligand: a possible mechanism for poor sensitivity to antitumor immunity.
Inukai T; Zhang X; Goto M; Hirose K; Uno K; Akahane K; Nemoto A; Goi K; Sato H; Takahashi K; Honna H; Kagami K; Nakamoto K; Yagita H; Okumura K; Koyama-Okazaki T; Nakazawa S; Sugita K
Leukemia; 2006 Dec; 20(12):2119-29. PubMed ID: 17066095
[TBL] [Abstract][Full Text] [Related]
2. Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis.
Akahane K; Inukai T; Zhang X; Hirose K; Kuroda I; Goi K; Honna H; Kagami K; Nakazawa S; Endo K; Kubota T; Yagita H; Koyama-Okazaki T; Sugita K
Exp Hematol; 2010 Oct; 38(10):885-95. PubMed ID: 20670671
[TBL] [Abstract][Full Text] [Related]
3. BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia.
Kuroda I; Inukai T; Zhang X; Kikuchi J; Furukawa Y; Nemoto A; Akahane K; Hirose K; Honna-Oshiro H; Goi K; Kagami K; Yagita H; Tauchi T; Maeda Y; Sugita K
Oncogene; 2013 Mar; 32(13):1670-81. PubMed ID: 22665066
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptors.
Zhang X; Inukai T; Hirose K; Akahane K; Kuroda I; Honna-Oshiro H; Kagami K; Goi K; Nakamura K; Kobayashi M; Endo M; Yagita H; Kurosawa H; Thomas Look A; Honda H; Inaba T; Nakazawa S; Sugita K
Leukemia; 2012 Dec; 26(12):2483-93. PubMed ID: 22743623
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
6. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
7. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
8. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents.
Furuichi Y; Goi K; Inukai T; Sato H; Nemoto A; Takahashi K; Akahane K; Hirose K; Honna H; Kuroda I; Zhang X; Kagami K; Hayashi Y; Harigaya K; Nakazawa S; Sugita K
Cancer Res; 2007 Oct; 67(20):9852-61. PubMed ID: 17942916
[TBL] [Abstract][Full Text] [Related]
9. Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Spijkers-Hagelstein JA; Schneider P; Hulleman E; de Boer J; Williams O; Pieters R; Stam RW
Leukemia; 2012 Jun; 26(6):1255-65. PubMed ID: 22282267
[TBL] [Abstract][Full Text] [Related]
10. Monitoring mixed lineage leukemia expression may help identify patients with mixed lineage leukemia--rearranged acute leukemia who are at high risk of relapse after allogeneic hematopoietic stem cell transplantation.
Liu J; Wang Y; Xu LP; Liu DH; Qin YZ; Chang YJ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2014 Jul; 20(7):929-36. PubMed ID: 24631740
[TBL] [Abstract][Full Text] [Related]
11. A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction.
Somers K; Wen VW; Middlemiss SMC; Osborne B; Forgham H; Jung M; Karsa M; Clifton M; Bongers A; Gao J; Mayoh C; Raoufi-Rad N; Kusnadi EP; Hannan KM; Scott DA; Kwek A; Liu B; Flemming C; Chudakova DA; Pandher R; Failes TW; Lim J; Angeli A; Osterman AL; Imamura T; Kees UR; Supuran CT; Pearson RB; Hannan RD; Davis TP; McCarroll J; Kavallaris M; Turner N; Gudkov AV; Haber M; Norris MD; Henderson MJ
Oncogene; 2019 May; 38(20):3824-3842. PubMed ID: 30670779
[TBL] [Abstract][Full Text] [Related]
12. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
Riccioni R; Pasquini L; Mariani G; Saulle E; Rossini A; Diverio D; Pelosi E; Vitale A; Chierichini A; Cedrone M; Foà R; Lo Coco F; Peschle C; Testa U
Haematologica; 2005 May; 90(5):612-24. PubMed ID: 15921376
[TBL] [Abstract][Full Text] [Related]
13. MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Carrillo E; Sánchez J; Pérez-López O; Pérez de Soto I; González Campos J; Prats-Martín C; Bernal R; Vargas MT
Eur J Haematol; 2018 May; 100(5):436-443. PubMed ID: 29384595
[TBL] [Abstract][Full Text] [Related]
14. Targeting epigenetic programs in MLL-rearranged leukemias.
Bernt KM; Armstrong SA
Hematology Am Soc Hematol Educ Program; 2011; 2011():354-60. PubMed ID: 22160057
[TBL] [Abstract][Full Text] [Related]
15. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
[TBL] [Abstract][Full Text] [Related]
16. [Clinical and molecular biologic characteristics of 36 cases of leukemia with 11q23/mll].
Zhao J; Yin YM; Zhao YL; Sun Y; Wang JB; Zhong J; Zhang X; Fei XH; Shan FX; Liu HX; Wang T; Wang H; Tong CR; Wu T; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1381-5. PubMed ID: 21176334
[TBL] [Abstract][Full Text] [Related]
17. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Spijkers-Hagelstein JA; Mimoso Pinhanços S; Schneider P; Pieters R; Stam RW
Leukemia; 2013 Apr; 27(5):1063-71. PubMed ID: 23334362
[TBL] [Abstract][Full Text] [Related]
18. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements.
Ando N; Furuichi Y; Kasai S; Tamai M; Harama D; Kagami K; Abe M; Goi K; Inukai T; Sugita K
Leuk Res; 2018 Dec; 75():36-44. PubMed ID: 30453100
[TBL] [Abstract][Full Text] [Related]
20. Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement.
Bardini M; Woll PS; Corral L; Luc S; Wittmann L; Ma Z; Lo Nigro L; Basso G; Biondi A; Cazzaniga G; Jacobsen SE
Leukemia; 2015 Jan; 29(1):38-50. PubMed ID: 24798483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
